Sera Prognostics, Inc. Stock Price, News & Analysis

Sera Prognostics, Inc. (Nasdaq: SERA), a leader in maternal health diagnostics, will present at the 42nd Annual William Blair Growth Stock Conference on June 7, 2022, at 3:20 p.m. CT. CEO Gregory C. Critchfield will discuss the company's latest developments, including its innovative PreTRM® test, which predicts premature birth risk. The event will be available via live webcast on Sera's Investor website. Sera aims to improve healthcare outcomes for mothers and infants through precision medicine and has a significant pipeline focused on pregnancy-related complications.

Sera Prognostics, Inc. (NASDAQ: SERA) published data showing improved performance of its PreTRM® test for predicting spontaneous preterm birth. The study demonstrated an 88% sensitivity and 99% negative predictive value, indicating increased accuracy and reliability. The test can now be performed more conveniently during pregnancy, enhancing access for women at risk. These findings were published in the Journal of Clinical Medicine and align with updated ACOG gestational age guidelines, emphasizing Sera's commitment to improving maternal health.

Sera Prognostics (Nasdaq: SERA) presented data on the PreTRM® test-and-treat strategy at the ISPOR 2022 conference in Washington, DC. The study analyzed the effects of two intervention strategies on high-risk pregnancies using the PreTRM® Test. Results showed a significant reduction in neonatal hospital stays by 22% and maternal stays by 8.5%. Furthermore, moderate-to-severe neonatal morbidity dropped by 29%. The findings highlight the economic benefits and potential cost savings of proactive interventions in pregnancy care.

Sera Prognostics (Nasdaq: SERA) reported its Q1 2022 financial results, showing revenue of $38,000, up from $13,000 in Q1 2021. Operating expenses surged to $12.3 million, compared to $6.0 million a year earlier. The net loss increased to $12.2 million from $6.4 million. The company ended the quarter with approximately $64.1 million in cash and equivalents. Key highlights included a streamlined PreTRM® test ordering process and advancing clinical studies. The ongoing PRIME study aims to enhance neonatal outcomes and reduce healthcare costs.

Sera Prognostics, Inc. (NASDAQ: SERA) and the Newborn Foundation have partnered to launch the Every Mother, Every Baby Project aimed at reducing maternal and neonatal mortality linked to preterm birth. This initiative focuses on educating healthcare professionals and improving access to biomarker-based tests like Sera's PreTRM® test, crucial for identifying at-risk pregnancies. The project aims for equitable health outcomes by addressing policy frameworks and ensuring standardized testing reimbursement. Over 60% of infant deaths occur during the neonatal period, with preterm birth a significant contributor.

Sera Prognostics, Inc., the Pregnancy Company® (Nasdaq: SERA), will release its first quarter fiscal year 2022 financial results on May 10, 2022, after market close. A conference call and live webcast will follow at 5:00 p.m. ET to discuss operational highlights and financial metrics. Sera specializes in maternal and neonatal health through innovative diagnostics like the PreTRM® test, which predicts preterm birth risk. The company aims to improve pregnancy outcomes and reduce healthcare costs associated with complications of prematurity.

Sera Prognostics announced the appointment of Dr. Jane F. Barlow to its Board of Directors, effective April 12, 2022. Dr. Barlow is recognized for her executive experience in health services and consulting, including roles as CEO of her own firm and Chief Clinical Officer at Real Endpoints. Her expertise is expected to bolster Sera's mission to enhance maternal and neonatal health with innovative diagnostics, including the PreTRM® test, which identifies preterm birth risk. CEO Gregory C. Critchfield highlighted Dr. Barlow's potential contributions towards improving healthcare outcomes and reducing costs.

Sera Prognostics Inc. (SERA) reported its Q4 and full-year 2021 financial results, highlighting a revenue increase to $26,000 in Q4 2021 from $6,000 in Q4 2020 and $82,000 for the full year compared to $25,000 in 2020. Operating expenses rose significantly, totaling $12.6 million in Q4, primarily due to increased commercial operations and R&D costs. The company reported a net loss of $12.5 million for Q4 2021, up from $5.4 million in the previous year. Sera also announced new partnerships and ongoing market expansion efforts aimed at improving the adoption of its PreTRM® Test.

Sera Prognostics (Nasdaq: SERA) presented findings at the 69th Annual Meeting of the Society for Reproductive Investigation. The study analyzed over 10,500 patients to evaluate the prediction of preeclampsia using 31 protein biomarkers and 6 clinical factors. Key results showed that previous preeclampsia was a strong predictor, while 7 biomarkers effectively predicted preeclampsia and 5 predicted preterm preeclampsia. The study highlights Sera's commitment to improving maternal health through innovative diagnostics.